Bairavi Shankar1,2, Jiajia Zhang1,2, Abdul Rafeh Naqash3,4, Patrick M Forde1,2, Josephine L Feliciano1,2, Kristen A Marrone1,2, David S Ettinger1,2, Christine L Hann1,2, Julie R Brahmer1,2, Biagio Ricciuti5,6, Dwight Owen7, Yukihiro Toi8, Paul Walker3, Gregory A Otterson7, Sandip H Patel7, Shunichi Sugawara8, Jarushka Naidoo1,2,9. 1. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland. 2. Bloomberg Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland. 3. Division of Hematology/Oncology, East Carolina University, Greenville, North Carolina. 4. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland. 5. Department of Oncology, University of Perugia, Perugia, Italy. 6. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 7. The Ohio State University-James Comprehensive Cancer Center, the Ohio State University, Columbus. 8. Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan. 9. The Royal College of Surgeons of Ireland, Beaumont Hospital Dublin, Ireland.
Abstract
Importance: The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described. Objective: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development. Design, Setting, and Participants: This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)1 ICIs alone or in combination with another anticancer agent between January 2007 and January 2019. Exposures: Anti-PD-(L)1 monotherapy or combinations. Main Outcomes and Measures: Multisystem irAEs were characterized by combinations of individual irAEs or organ system involved, separated by ICI-monotherapy or combinations. Median progression-free (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed by multivariable models. Risk for multisystem irAE was estimated as odds ratios by multivariable logistic regression. Results: The 623 patients included in the study were mostly men (60%, n = 375) and White (77%, n = 480). The median (range) age was 66 (58-73) years, and 148 patients (24%) developed a single irAE, whereas 58 (9.3%) developed multisystem irAEs. The most common multisystem irAE patterns in patients receiving anti-PD-(L)1 monotherapy were pneumonitis thyroiditis (n = 7, 14%), hepatitis thyroiditis (n = 5, 10%), dermatitis pneumonitis (n = 5, 10%), and dermatitis thyroiditis (n = 4, 8%). Favorable Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS = 0/1 vs 2; adjusted odds ratio [aOR], 0.27; 95% CI, 0.08-0.94; P = .04) and longer ICI duration (aOR, 1.02; 95% CI, 1.01-1.03; P < .001) were independent risk factors for development of multisystem irAEs. Patients with 1 irAE and multisystem irAEs demonstrated incrementally improved OS (adjusted hazard ratios [aHRs], 0.86; 95% CI, 0.66-1.12; P = .26; and aHR, 0.57; 95% CI, 0.38-0.85; P = . 005, respectively) and PFS (aHR, 0.68; 95% CI, 0.55-0.85; P = .001; and aHR, 0.39; 95% CI, 0.28-0.55; P < .001, respectively) vs patients with no irAEs, in multivariable models adjusting for ICI duration. Conclusions and Relevance: In this multicenter cohort study, development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs.
Importance: The spectrum of individual immune-related adverse events (irAEs) from anti-programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has been reported widely, and their development is associated with improved patient survival across tumor types. The spectrum and impact on survival for patients with non-small cell lung cancer (NSCLC) who develop multisystem irAEs from ICIs, has not been described. Objective: To characterize multisystem irAEs, their association with survival, and risk factors for multisystem irAE development. Design, Setting, and Participants: This retrospective cohort study carried out in 5 academic institutions worldwide included 623 patients with stage III/IV NSCLC, treated with anti-PD-(L)1 ICIs alone or in combination with another anticancer agent between January 2007 and January 2019. Exposures: Anti-PD-(L)1 monotherapy or combinations. Main Outcomes and Measures: Multisystem irAEs were characterized by combinations of individual irAEs or organ system involved, separated by ICI-monotherapy or combinations. Median progression-free (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Differences in PFS and OS between irAE groups were assessed by multivariable models. Risk for multisystem irAE was estimated as odds ratios by multivariable logistic regression. Results: The 623 patients included in the study were mostly men (60%, n = 375) and White (77%, n = 480). The median (range) age was 66 (58-73) years, and 148 patients (24%) developed a single irAE, whereas 58 (9.3%) developed multisystem irAEs. The most common multisystem irAE patterns in patients receiving anti-PD-(L)1 monotherapy were pneumonitis thyroiditis (n = 7, 14%), hepatitis thyroiditis (n = 5, 10%), dermatitis pneumonitis (n = 5, 10%), and dermatitis thyroiditis (n = 4, 8%). Favorable Eastern Cooperative Oncology Group (ECOG) performance status (PS) (ECOG PS = 0/1 vs 2; adjusted odds ratio [aOR], 0.27; 95% CI, 0.08-0.94; P = .04) and longer ICI duration (aOR, 1.02; 95% CI, 1.01-1.03; P < .001) were independent risk factors for development of multisystem irAEs. Patients with 1 irAE and multisystem irAEs demonstrated incrementally improved OS (adjusted hazard ratios [aHRs], 0.86; 95% CI, 0.66-1.12; P = .26; and aHR, 0.57; 95% CI, 0.38-0.85; P = . 005, respectively) and PFS (aHR, 0.68; 95% CI, 0.55-0.85; P = .001; and aHR, 0.39; 95% CI, 0.28-0.55; P < .001, respectively) vs patients with no irAEs, in multivariable models adjusting for ICI duration. Conclusions and Relevance: In this multicenter cohort study, development of multisystem irAEs was associated with improved survival in patients with advanced NSCLC treated with ICIs.
Authors: V Ellen Maher; Laura L Fernandes; Chana Weinstock; Shenghui Tang; Sundeep Agarwal; Michael Brave; Yang-Min Ning; Harpreet Singh; Daniel Suzman; James Xu; Kirsten B Goldberg; Rajeshwari Sridhara; Amna Ibrahim; Marc Theoret; Julia A Beaver; Richard Pazdur Journal: J Clin Oncol Date: 2019-05-22 Impact factor: 44.544
Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544
Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245
Authors: Louis Fehrenbacher; Joachim von Pawel; Keunchil Park; Achim Rittmeyer; David R Gandara; Santiago Ponce Aix; Ji-Youn Han; Shirish M Gadgeel; Toyoaki Hida; Diego L Cortinovis; Manuel Cobo; Dariusz M Kowalski; Filippo De Marinis; Mayank Gandhi; Bradford Danner; Christina Matheny; Marcin Kowanetz; Pei He; Federico Felizzi; Hina Patel; Alan Sandler; Marcus Ballinger; Fabrice Barlesi Journal: J Thorac Oncol Date: 2018-05-17 Impact factor: 15.609
Authors: Shintaro Iwama; Alessandra De Remigis; Margaret K Callahan; Susan F Slovin; Jedd D Wolchok; Patrizio Caturegli Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff Journal: J Immunother Cancer Date: 2017-11-21 Impact factor: 13.751
Authors: Kennedy Yao Yi Ng; Sze Huey Tan; Jack Jie En Tan; Desiree Shu Hui Tay; Ailica Wan Xin Lee; Andrea Jing Shi Ang; Lawrence Wen Jun Wong; Su Pin Choo; David Wai-Meng Tai; Joycelyn Jie Xin Lee Journal: Liver Cancer Date: 2021-10-26 Impact factor: 11.740
Authors: Daniel V Araujo; Bruno Uchoa; Juan José Soto-Castillo; Larissa L Furlan; Marc Oliva Journal: Target Oncol Date: 2022-06-10 Impact factor: 4.864
Authors: Jia Luo; Victoria L Martucci; Alexander Gusev; Melinda C Aldrich; Matthew D Hellmann; Elad Ziv; Zoe Quandt; Stefan Groha; Megan H Murray; Christine M Lovly; Hira Rizvi; Jacklynn V Egger; Andrew J Plodkowski; Mohsen Abu-Akeel; Isabell Schulze; Taha Merghoub; Eduardo Cardenas; Scott Huntsman; Min Li; Donglei Hu; Matthew A Gubens Journal: Clin Cancer Res Date: 2021-07-08 Impact factor: 12.531
Authors: Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751
Authors: Lea Daniello; Mariam Elshiaty; Farastuk Bozorgmehr; Jonas Kuon; Daniel Kazdal; Hannah Schindler; Rajiv Shah; Anna-Lena Volckmar; Fabienne Lusky; Leonore Diekmann; Stephan Liersch; Martin Faehling; Thomas Muley; Mark Kriegsmann; Karolina Benesova; Albrecht Stenzinger; Michael Thomas; Petros Christopoulos Journal: Front Oncol Date: 2021-06-29 Impact factor: 6.244
Authors: Kikkie Poels; Suzanne I M Neppelenbroek; Marie José Kersten; M Louisa Antoni; Esther Lutgens; Tom T P Seijkens Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751